相关临床试验
22
20 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
20
90.9%
已完成
1
4.5%
暂停
1
4.5%
暂无批准数据
- Loss of one copy of the DNA Ligase I (LIG1) gene in TP53-mutant triple-negative breast cancers is robustly associated with platinum-based chemotherapy resistance. - Researchers identified that combining the PARP inhibitor olaparib with the ATR inhibitor ceralasertib was significantly more effective than either drug alone in LIG1-loss models. - The study, published in Molecular Cancer Therapeutics, demonstrated reduced tumor growth in animal models using this combination strategy. - LIG1 status may serve as a predictive biomarker to stratify TNBC patients for future clinical trials evaluating ATR/PARP inhibitor combinations.
- Staff at the Institute of Cancer Research (ICR) have extended strike action for the first time in the institute's 117-year history, with the walkout now set to run through August 7. - Unite the Union representatives describe pay negotiations as "hostile," claiming some researchers are skipping meals, struggling with bills, and taking second jobs to make ends meet. - A union survey found 79% of striking workers are worse off than 12 months ago, and more than 60% are looking to leave their roles due to the working environment. - The ICR maintains its pay offer is above inflation, equating to at least a 12.5% salary increase over three years, and says it remains committed to constructive negotiations.
- The Biomede trial, testing a US-approved drug combined with radiotherapy for DIPG, has been delayed in the UK due to post-Brexit regulatory divergence from the EU framework established in 2022. - Approximately 30 UK children are diagnosed annually with DIPG, an incurable brainstem tumour with a survival rate of "essentially zero," where most children die within two to three years of diagnosis. - Cancer Research UK reports that nine in 10 children's cancer doctors rely on international funding for trials, and the lack of UK-EU harmonisation has driven families to seek treatment overseas. - The MHRA says new regulations from April 2026 will strengthen alignment with international standards, but experts and charities urge immediate action to prevent treatment gaps.
- A first-in-human study confirms high-intensity focused ultrasound (HIFU) can safely block abnormal placental blood vessels in early-onset twin-to-twin transfusion syndrome (TTTS). - The non-invasive procedure successfully blocked blood flow in 90% of treated vessels with no adverse side effects, though half of the 10 participants required further treatment. - Researchers are now planning a larger trial of 50 to 100 women to determine whether HIFU can stabilize or reverse TTTS as an alternative to invasive laser therapy. - TTTS affects 10–15% of identical twins sharing a placenta, representing approximately 300–400 pregnancies annually in the UK, with potentially fatal outcomes if untreated.
- Outrun Therapeutics has selected a first-in-class E6AP ubiquitin ligase inhibitor as its lead programme for treating HPV-positive head and neck cancer, with clinical entry expected in 2027. - The novel therapeutic strategy aims to stabilize tumor suppressor proteins by inhibiting E6AP, targeting an underserved patient population representing 4.5% of cancers worldwide. - The company has assembled a world-class Scientific Advisory Board including renowned experts in E3 ligase biology and head and neck cancer to guide clinical development. - The programme has demonstrated strong preclinical proof of mechanism both in vitro and in vivo, positioning it as a potential breakthrough treatment for this challenging indication.
- The London Cancer Hub receives approval for a £1bn expansion that will create 3,000 new jobs and add one million square feet of laboratory and research space in Sutton. - The expansion is projected to contribute £1.2bn in Gross Value Added to the UK economy while strengthening the country's position in global oncology research. - The development aligns with the UK government's Life Sciences Sector Plan and National Cancer Plan for England, aimed at maintaining competitiveness amid recent industry setbacks.
- The Institute of Cancer Research, London, has developed OPTIMISE-ROR, the first foundational guidance for incorporating patient-reported outcomes into early phase dose-finding cancer trials. - The international consensus-based recommendations address six core areas focusing on treatment tolerability, side effect impact, and quality of life assessment across dose levels. - The guidelines aim to improve clinical interpretation of patient experience data and enhance decision-making for dose escalation and optimization in cancer drug development. - Published in the Journal of Clinical Oncology, the work addresses a critical gap where many early phase trials lack clear standards for defining patient-reported outcome objectives.
- Agora Open Science Trust has nominated M4K2009 as the lead development candidate for treating Diffuse Intrinsic Pontine Glioma (DIPG), a rare and devastating pediatric brain cancer. - The ALK2 inhibitor demonstrated excellent potency, selectivity, brain penetration, and tolerability in preclinical models after evaluation of hundreds of compounds through multi-year collaborative research. - This milestone represents a significant advancement in open science drug discovery, with the program now moving into IND-enabling studies toward clinical trials. - The development was supported by multiple international partners and Canada's Strategic Innovation Fund through Conscience's Developing Medicines through Open Science program.
- Researchers at the Institute of Cancer Research are developing innovative formulation and prodrug strategies to overcome the physicochemical limitations that prevent oral delivery of VHL-based PROTACs. - The comprehensive approach includes screening 10-20 PROTAC molecules against diverse formulation types and synthesizing prodrugs to enhance permeability through modulating lipophilicity and blocking hydrogen-bond donor groups. - Advanced delivery platforms including self-emulsifying drug delivery systems, lipid-based carriers, and polymeric nanocarriers will be evaluated to address solubility, permeability and stability challenges. - The project aims to create a practical toolkit for selecting and developing formulations compatible with PROTACs, supporting faster progression to proof-of-concept studies.
- A phase II trial of zongertinib as first-line treatment for advanced HER2-mutant lung cancer achieved a 77% overall response rate, with 8% of patients experiencing complete tumor disappearance. - The targeted therapy demonstrated disease control in 96% of patients, offering a new treatment option for the 4% of lung cancer cases driven by HER2 mutations. - Results presented at ESMO Congress represent the first study of zongertinib as initial treatment, with a phase III trial planned to compare against standard chemotherapy.
